» Articles » PMID: 26746183

A Rapid Functional Decline Type of Amyotrophic Lateral Sclerosis is Linked to Low Expression of TTN

Abstract

Objective: To classify the patterns of functional decline in patients with sporadic amyotrophic lateral sclerosis (ALS) and explore the genetic backgrounds that modified these patterns.

Methods: We included 465 patients with sporadic ALS in the analysis and clustered the longitudinal functional scores in the registered patients, using a mixture approach of a non-linear mixed-effects model. We conducted a genome-wide analysis of 572 983 single nucleotide polymorphisms (SNPs). We then assessed the association between the clusters of longitudinal functional scores and SNPs.

Results: We identified the following four clusters of longitudinal functional decline in the cases: a rapid decline cluster, an intermediate decline cluster, a sigmoidal decline cluster and a moderate decline cluster. We identified seven SNPs associated with the rapid decline cluster, using a recessive model (p=3.47-8.34×10(-8)). The OR for the probabilities of the rapid decline cluster ranged from 5.5 to 5.84. Homozygosity for the minor alleles in the seven SNPs, which constituted a linkage disequilibrium (LD) block, was associated with decreased expression of TTN (encoding Titin, a large sarcomere protein) in the expression quantitative trait loci database of a large-scale Japanese genetic variation database (p=8.6×10(-10)-1.1×10(-7)). TTN expression in immortalised lymphocyte lines was decreased in patients who were homozygous for the minor alleles compared with those who were homozygous for the major alleles (n=19 in each group, p=0.002).

Conclusions: We detected an LD block associated with a rapid functional decline in patients with sporadic ALS, which is linked to decreased expression of TTN.

Citing Articles

Complex Genetic Framework in Familial Amyotrophic Lateral Sclerosis With a C9ORF72 Mutation: A Case Report.

Frolov A, Dsa E, Henderson C, Guzman M, Hayat G, Martin 3rd J Cureus. 2025; 16(12):e76027.

PMID: 39835009 PMC: 11743604. DOI: 10.7759/cureus.76027.


Onset of age, site and respiratory symptoms are strongly associated with respiratory decline in sporadic amyotrophic lateral sclerosis: a long-term longitudinal study.

Terao S, Nosaki Y, Murao A, Torii R, Ogawa N, Miura N BMJ Neurol Open. 2024; 6(2):e000829.

PMID: 39720511 PMC: 11667433. DOI: 10.1136/bmjno-2024-000829.


Protocol for a phase 2 study of bosutinib for amyotrophic lateral sclerosis using real-world data: induced pluripotent stem cell-based drug repurposing for amyotrophic lateral sclerosis medicine (iDReAM) study.

Imamura K, Izumi Y, Egawa N, Ayaki T, Nagai M, Nishiyama K BMJ Open. 2024; 14(10):e082142.

PMID: 39461864 PMC: 11529471. DOI: 10.1136/bmjopen-2023-082142.


Large-scale differentiation of iPSC-derived motor neurons from ALS and control subjects.

Workman M, Lim R, Wu J, Frank A, Ornelas L, Panther L Neuron. 2023; 111(8):1191-1204.e5.

PMID: 36764301 PMC: 10557526. DOI: 10.1016/j.neuron.2023.01.010.


Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial.

Imamura K, Izumi Y, Nagai M, Nishiyama K, Watanabe Y, Hanajima R EClinicalMedicine. 2022; 53:101707.

PMID: 36467452 PMC: 9716331. DOI: 10.1016/j.eclinm.2022.101707.